Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.65 |
| ▸ | BRD4 | O60885 | 5/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | GPR4 | P46093 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL748457 | 0.96 | AR (0.60) | ARBRD4KCNH2MAPTHPGD | |
| SCHEMBL748087 | 0.89 | BRD4 (0.83) | ARBRD4KCNH2GPR4 | |
| SCHEMBL751236 | 0.88 | BRD4 (0.61) | ARBRD4KCNH2MAPTHPGD | |
| SCHEMBL748875 | 0.86 | AR (0.73) | ARBRD4KCNH2MAPTHPGD | |
| SCHEMBL3067912 | 0.85 | BRD4 (0.77) | ARBRD4KCNH2 | |
| SCHEMBL2268416 | 0.85 | HTT (0.59) | ARBRD4KCNH2MAPTHPGD | |
| SCHEMBL750060 | 0.82 | BRD4 (0.79) | ARBRD4KCNH2MAPTHPGD | |
| SCHEMBL2266249 | 0.82 | HTT (0.61) | ARBRD4KCNH2MAPTHPGD | |
| SCHEMBL752905 | 0.80 | MAPT (0.65) | ARBRD4KCNH2MAPTHPGD | |
| SCHEMBL746988 | 0.79 | BRD4 (1.00) | ARBRD4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885BRD4 622/4885KCNH2 2070/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885BRD4 628/4885KCNH2 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.